Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q14331

UPID:
FRG1_HUMAN

ALTERNATIVE NAMES:
FSHD region gene 1 protein

ALTERNATIVE UPACC:
Q14331; A8K775

BACKGROUND:
FSHD region gene 1 protein (FRG1) is integral to mRNA binding, pre-mRNA splicing regulation, rRNA assembly, and mRNA transport. It also plays a pivotal role in muscle differentiation through epigenetic mechanisms, affecting histone-lysine N-methyltransferase KMT5B activity. These functions make FRG1 a key player in cellular and genetic regulatory mechanisms.

THERAPEUTIC SIGNIFICANCE:
FRG1's involvement in Facioscapulohumeral muscular dystrophy 1 (FSHD1) underscores its potential as a therapeutic target. Its overexpression in FSHD1 leads to muscle dystrophy, skeletal muscle atrophy, and abnormal mRNA splicing. Targeting FRG1's pathological overexpression and its downstream effects could offer new therapeutic avenues for treating FSHD1, emphasizing the importance of further research into FRG1's functions and mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.